Loading...
Docoh

EQRx (EQRX)

News

From Benzinga Pro
110 Biggest Movers From Friday
16 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
56 Stocks Moving In Friday's Mid-Day Session
13 May 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Veru Inc. (NASDAQ: VERU) shares jumped 62.5% to $14.67 after the company reported quarterly results on Thursday. Jefferies maintained Veru with a Buy and raised the price target from $33 to $55.
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
13 May 22
Biotech, Earnings, News, Penny Stocks, Health Care, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For May 13, 2022
13 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.08 million.
Benzinga's Top Ratings Upgrades, Downgrades For April 22, 2022
22 Apr 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Cowen & Co. Initiates Coverage On EQRx with Outperform Rating
22 Apr 22
News, Initiation, Analyst Ratings
Cowen & Co. analyst Steve Scala initiates coverage on EQRx (NASDAQ:EQRX) with a Outperform rating.
Earnings Scheduled For March 23, 2022
23 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter.
75 Biggest Movers From Yesterday
22 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares jumped 299.4% to close at $6.23 on Monday as the company received clearance from the FDA to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.
46 Stocks Moving In Monday's Mid-Day Session
21 Mar 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Benzinga's Top Ratings Upgrades, Downgrades For March 18, 2022
18 Mar 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Jefferies Initiates Coverage On EQRx with Buy Rating, Announces Price Target of $5.6
18 Mar 22
News, Price Target, Initiation, Analyst Ratings
Jefferies analyst Akash Tewari initiates coverage on EQRx (NASDAQ:EQRX) with a Buy rating and announces Price Target of $5.6.